Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flavopiridol Hoechst AG.

M J Zvelebil1

  • 1Ludwig Institute for Cancer Research, Courtauld Building, 91 Riding House Street, London, W1P 8BT, UK. marketa@ludwig.ucl.ac.uk

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.

The Journal of biological chemistry·2001
Same author

Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors.

Molecular and cellular biology·2000
Same author

Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer.

Genes, chromosomes & cancer·1999
Same author

Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.

Proceedings of the National Academy of Sciences of the United States of America·1999
Same author

Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity.

The Journal of biological chemistry·1998
Same author

1H NMR structure of an antifungal gamma-thionin protein SIalpha1: similarity to scorpion toxins.

Proteins·1998
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Flavopiridol, a synthetic flavonoid, inhibits cell division and induces apoptosis in cancer cells. Clinical trials are underway for lymphoma and multiple myeloma, showing promising results in preclinical studies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Flavopiridol is a synthetic flavonoid developed for cancer treatment.
  • It functions as a cyclin-dependent kinase (CDK) inhibitor, arresting cell division and inducing apoptosis.

Purpose of the Study:

  • To evaluate the potential of flavopiridol in cancer therapy.
  • To assess its efficacy and safety in preclinical and clinical settings.

Main Methods:

  • Phase II clinical trial for lymphoma and multiple myeloma.
  • Ex vivo experiments on chronic lymphoblastic leukemia cells.
  • In vitro pharmacokinetic studies and CDK inhibition assays.
  • Preclinical toxicology studies in rats and dogs.

Main Results:

Related Experiment Videos

  • Flavopiridol demonstrated dose-dependent CDK2 inhibition and apoptosis in leukemia cells.
  • Hepatic biotransformation to glucuronide via UDP-glucuronosyltransferases observed.
  • IC50 for CDK inhibition is 0.4 mM.
  • Preclinical studies showed dose-related leukopenia and organ toxicity, with gastrointestinal and bone marrow toxicity being dose-limiting.

Conclusions:

  • Flavopiridol exhibits anti-cancer properties by inhibiting cell division and inducing apoptosis.
  • Ongoing clinical trials will further define its therapeutic potential.
  • Toxicity profile requires careful management in clinical application.